Most children with asthma respond to low doses of inhaled corticosteroids, but a few remain symptomatic despite being prescribed the routine usual asthma medications. Th e fi rst steps are to ensure that the diagnosis is correct and that the inhaled medications are being given regularly with an appropriately used device. If the children continue to be symptomatic, with any or all of chronic symptoms, acute exacerbations, the need for regular oral corticosteroids, or persistent airfl ow limitation, then they are considered to have problematic, severe asthma. Th e next step is to perform a detailed evaluation, including a nurse-lead home visit, to determine whether the child has diffi cult to treat asthma which improves if the basics are got right, or severe, therapy-resistant asthma; the latter group would be candidates for cytokine-specifi c therapies. If severe, therapy-resistant asthma is the likely issue, then a detailed invasive investigation is performed, including bronchoscopy, bronchoalveolar lavage and endobronchial biopsy, and trial of adherence with a single intramuscular injection of depot triamcinolone. Aft er detailed phenotyping, an individualised treatment plan is determined. Future work will determine the roles of proximal and distal infl ammation, as well as the relative importance of intramural (mucosal) and intraluminal infection. Th e stability of paediatric asthma phenotypes over time is more variable than those of adults, and the implications of a change of phenotype are yet to be determined.
INTRODUCTION
As is well known, most children with asthma respond very well to low doses of inhaled corticosteroids (ICS); they do not require high-dose therapy, and indeed high dose ICS are actively harmful (1, 2) . So, contemplating a child with treatment non-responsive to therapy, the key question is: what is it about this child and his/her asthma which makes it diffi cult to treat?
Th e fi rst important point is that these children are rare; failure to respond to simple treatment is usually either due to wrong diagnosis or failure to get the basics right. Th ree recent studies illustrate this well. Th e fi rst was an attempt to discover whether azithromycin or montelukast were a better add-on therapy in children who had persistent asthma despite moderately high-dose ICS and long-acting β-2 agonists (3). 292 children were assessed for entry, but only 55 were randomised, and the study, which was negative, was futile for want of power. Th e key reasons for exclusion were mainly non-adherence to treatment or that the child could not be shown to have asthma. Th e other two studies were related to the use of exhaled nitric oxide (FeNO) to improve asthma control (4, 5) . In a study of inner city asthma, by the time the basics had been got right (proper, guideline-based therapy, with every eff ort being made to get the children to take it), asthma control was so much better that there was really little scope for further improvements by measuring FeNO (4) . In the third paper, FeNO telemonitoring to guide asthma therapy was compared to a standard regime (5) . Th ere was intensive input and monitoring in both limbs of the study, and both groups improved equally. So the lessons of these three studies are: (1) severe asthma may not be severe, or asthma; (2) if you do the simple things well (6) , then much of the problem will disappear. 'KISS' -Keep It Simple, Stupid -is not a bad rule in paediatrics! Is it asthma at all? Th e diff erential diagnosis encompasses virtually the whole of paediatric respirology. Again, the KISS approach is recommended; a detailed history and physical examination comes fi rst, rather than a multiplicity of tests. Points in the history and physical signs to be sought are summarised in Tables 1 and 2 , respectively, and the diff erential diagnosis and possible investigations in Tables 3 and 4 . None of these is exhaustive, and the key is to use clinical skills and experience.
Is the drug delivery device correct? Th is is oft en an issue that needs tackling (7, 8) . A review of medication delivery devices should be part of every asthma consultation; retention of information at a training session is notoriously poor a few weeks later. One problem is children being given spacers with a mask long aft er the mask can be dispensed with (usually at age 3 years). Another issue is the adolescent who discards the inhaler altogether and uses the metered dose inhaler directly into the mouth with predictably poor drug delivery, supposing that spacers are babyish. It is also becoming increasingly clear (below) that repetition of teaching is essential. Poor technique is common despite multiple attempts at instruction. Table 1 . Points to seek in the history suggesting an underlying serious diagnosis. A detailed history, targeted towards other respiratory conditions, is an essential fi rst step in evaluating the child with problematic, severe asthma Table 2 . Points to seek on examination suggesting an underlying serious diagnosis in a child with problematic asthma. Most children will have no physical signs; however, none will be found unless they are actively sought Table 3 . Diff erential diagnosis of problematic asthma, diseases which present as recurrent cough and wheeze These conditions need to be considered and excluded prior to escalating therapy
• Upper airway disease -adenotonsillar hypertrophy, rhinosinusitis, postnasal drip • Congenital structural bronchial disease -complete cartilage rings, cysts, webs • Bronchial / tracheal compression -vascular rings, pulmonary and sling, enlarged cardiac chamber or great vessel, lymph nodes enlarged by tuberculosis or lymphoma • Endobronchial disease -foreign body, tumour • Oesophageal / swallowing problems -refl ux, incoordinate swallow, laryngeal cleft or tracheo-oesophageal fi stula • Causes of pulmonary suppuration -cystic fi brosis, primary ciliary dyskinesia, persistent bacterial bronchitis, any systemic immunodefi ciency including agammaglobulinaemia, severe combined immunodefi ciency Misc. -bronchopulmonary dysplasia, congenital or acquired tracheomalacia, pulmonary oedema secondary to left-toright shunting or cardiomyopathy Table 4 . Investigations to be considered in the child with problematic asthma, if an alternative diagnosis is suspected A selective approach is necessary, depending on what clues have been elicited from history, examination and simple investigations
• Suspected upper airway disease -polysomnography, RAST or skin prick tests (radiograph of postnasal space is rarely useful), MRI or CT of sinuses • Known or suspected neuromuscular disease with dysfunctional swallow -speech and language therapy assessment, which may be combined with videofl uoroscopy • Suspected aspiration with normal neurology and no refl ux -rigid bronchoscopy to exclude laryngeal cleft and Htype fi stula • Suspected oesophageal disease -pH probe, barium swallow, tube oesophagram, oesophagoscopy • Suspected cystic fi brosis -sweat test, nasal potentials, genotype, stool elastase, three day faecal fat collection • Suspected primary ciliary dyskinesia -saccharine test, nasal ciliary motility, electron microscopy including orientation studies, nasal and exhaled nitric oxide, culture of ciliary brush biopsy, genetic studies becoming available • Suspected systemic immunodefi ciency -immunoglobulins and subclasses; vaccine antibodies; lymphocyte subsets; lymphocyte and neutrophil function tests; HIV test; referral to paediatric immunologist • Suspected structural airway disease -fi breoptic bronchoscopy • Suspected tuberculosis -Heaf test, fi breoptic bronchoscopy and / or gastric lavage, combined with culture and PCR;
ELISPOT, QUANTIFERON • Suspected cardiovascular disease -echocardiogram, barium swallow to exclude a vascular ring or pulmonary artery sling, angiography (usually CT or MRI) • Suspected bronchiectasis -high-resolution CT scan, investigations for local or systemic immunodefi ciency
PROBLEMATIC, SEVERE ASTHMA
Th is has been proposed as an umbrella term to describe the children referred with suspected asthma not responding to treatment (9) . Entry criteria are defi ned as one or more of (10, 11):
1. Persistent (most days, for at least 3 months) chronic symptoms (the necessity because of symptoms for shortacting β-2 agonists at least three times / week) of airways obstruction despite high dose medication (800 mcg/day budesonide equivalent, plus administration or failed trials of long-acting β-2 agonist, leukotriene receptor antagonist, and low-dose theophylline). Th is group would include Type 1 brittle asthma (12) , although this patient group would need to be clearly and separately defi ned in any data analysis.
2. Recurrent severe asthma exacerbations despite any appropriate allergen avoidance, and attempts with medication (which, depending on the clinical context, would include trials of low-dose daily inhaled corticosteroids (13, 14) , intermittent leukotriene receptor antagonists (15, 16) or intermittent high-dose inhaled corticosteroids (16, 17) ) to abort exacerbations, that have required:
either at least one admission to an intensive care unit, or at least two hospital admissions requiring intravenous medication/s, or ≥2 courses of oral steroids during the last year, despite the above therapy.
Th is group would include Type 2 brittle asthma (12), although this patient group would need to be clearly and separately defi ned in any data analysis.
3. Persistent airfl ow obstruction: post-oral steroid, postbronchodilator Z score < -1.96 with normative data from appropriate reference populations (18) despite the above therapy. 4 . Th e necessity of prescription of alternate day or daily oral steroids to achieve control of asthma.
Another important concept is that of risk. Future risk includes: risk of failure of normal lung growth (children) or accelerated decline in lung function (adults); risk of future loss of asthma control; risk of future exacerbations; risk of phenotype change from episodic, viral to multi-trigger (mainly pre-school children) (19) ; risk of harm from medications. Th is category, although important, is one that is likely more important to professionals than it is to patients.
Inherent also is that the concepts of acute exacerbations and baseline control, although overlapping, are not the same thing (20) . Loss of baseline control is, for example, characterized by a wide diurnal peak expiratory fl ow variation, while acute exacerbation is shown by a steep decline in peak fl ow, with no increased variability (20) . Acute exacerbations are almost invariably virally mediated (13) , although, at least in older children, the likelihood of admission to hospital with an exacerbation is greatest if there is also allergen sensitization combined with high levels of exposure to that allergen (13) .
Children meeting these criteria are referred to as problematic, severe asthma. Th is is an umbrella term, comprising children with diffi cult to treat asthma, and severe, therapyresistant asthma. In order to be in this category, all reasonable eff orts to eliminate other, non-asthma, diagnoses must have been made. Appropriate tests will vary with the age of the child and the clinical context.
Diffi cult to treat asthma is the category in which poor response is due to issues such as poor adherence to medication; adverse environmental circumstances such as passive smoke or allergen exposure; psychosocial issues, including dysfunctional breathing; and co-morbidities such as rhinosinusitis and gastro-oesophageal refl ux. Although the identifi cation of these issues may not make the asthma easy to treat, these children would not be candidates for expensive, inconvenient and potentially toxic cytokine-specifi c therapies.
Severe, therapy-resistant asthma comprises those children who still remain in one of the above four categories, despite attention to co-morbidities and the other factors described above. Th is is not a homogeneous group, and it should be sub-phenotyped. Th e best way to do this is unclear, but the selection of a high sputum eosinophil group of asthmatics for recent trials of anti-IL5 (21, 22) underscores the need to split rather than lump together these children.
In our practice, children with problematic, severe asthma are severely disabled. We studied 71 children (35 male), 21 of whom were using regular oral steroids (23) . Th e mean dose of fl uticasone equivalent was 1 mg/day, range 0.5 to 3 mg/day. Th ey had a median of 2 admissions to hospital, range 0-21, and 12 were ventilated on at least one occasion. Mean fi rst second forced expired volume in one second (FEV 1 ) was 76% (range 33-125), and, despite prescribed medication, median bronchodilator reversibility was 14% (range 12-106); 34% had persistent airfl ow limitation, defi ned here as FEV 1 <75%, predicted despite prednisolone and high-dose β-2 agonists; 97% had current symptoms with an asthma control test (15) less than 20. Median FeNO was 52 ppb (range 5-171, normal <25). Atopy was common, with more than 50% being skin prick test (SPT) positive to house dust mite (HDM), grasses, cat and dog. Food sensitivity, at least as judged by SPT, was common (peanut 25%, egg and milk 5-10%); this has been reported before as an association of severe asthma (24, 25) . Th ese children are now investigated using a staged protocol.
Problematic, severe asthma: the fi rst stage of the protocol. Th e fi rst step is always a review of diagnoses and medication delivery devices (above). Th ereaft er, if it is clear that the problem continues, a detailed nurse-lead review is undertaken, including visits to the home and school. Th e home visit has proven particularly valuable. An overall assessment is performed, and four issues are re-addressed in detail: psychosocial, adherence, allergens, and smoking (active and passive).
Psychosocial morbidity. Th is is common in our series; nearly 50% have a formal psychological assessment. It is not useful to try to determine whether the psychosocial issues caused the asthma, or the asthma, by interfering with lifestyle, for example, caused the psychosocial issues. If both are present, then both should be addressed on their merits. Parental or child, or both, may have anxiety or depression, and dysfunctional breathing is not uncommon. Th ese issues have of course been discussed previously, but parents seem more ready to discuss these sensitive issues at home, and 75% of the referrals come only aft er the home visit (26, 27) .
Adherence to medication. Th is is, of course, one of the hardest issues to determine. One method is to access the prescriptions collected from the general practice (28) . Mere collection of a prescription does not equate to the medication being taken, but no prescription collected certainly means that none has been inhaled. In our series, less than 50% had collected enough prescriptions for them to have taken more than 80% of their medications, 30% of patients had collected less than 50% of their prescriptions, and nearly 25% could not readily produce a complete set of in-date medications at the home visits. Despite repeated tuition, nearly 40% did not have a good technique with their inhaled medications. Finally, the issue of parental supervision of medication was addressed.
In an American study, 25% of 7 year olds and 50% of 11 year olds are expected to assume responsibility for their medications (29) ; I doubt that this is appropriate. In our group, it emerged oft en that although mothers reminded children, frequently, in the business of family life, they did not actually stand over them to witness the inhalers being used.
Allergen exposure. Th e allergens which we focus on in particular are house dust mite and pets. HDM avoidance precautions were only rigorous in 16% of households. In terms of pets, 30 households had pets, 17 children were sensitized to the pet, but in only two there was any attempt at allergen avoidance being made.
Allergen avoidance is controversial. A Cochrane review concluded that there was no value in HDM avoidance (30) . However, the review was fl awed in many ways; studies in which HDM allergen levels were not reduced were included, children and adults were lumped as one, and very short-term studies were all uncritically lumped together; in my view, it is not possible to draw conclusions from this review. Furthermore, HDM avoidance, if done properly, is expensive and inconvenient, and is unlikely to be done effi ciently unless the family perceives there is a major problem making the disruption of home life, and the expense of the intervention, likely to be worthwhile. Th e evidence in favour of allergen exposure is discussed below.
Tobacco smoke exposure. Salivary cotinine levels were high in around a third of children whose parents said they did not smoke, and in virtually all the children of smokers, irrespective of whether the parents claimed to smoke outside. At least two children acknowledged they were active smokers. Active smoking, and presumably also passive smoke exposure, is known to be a cause of steroid resistance (31) (32) (33) (34) .
School visit. Th e attendance record is checked. We also fi nd out the school's perception of the level of symptoms, which may sometimes diff er signifi cantly from what is reported in clinic. Th e school asthma policy may need to be discussed, and issues about ensuring that asthma does not prevent access to education are highlighted.
Does it work? As a result of this process, around half the children referred are placed in the 'diffi cult' rather than the 'severe, therapy-resistant' category and do not proceed to more detailed interventions. Th e changes made as a result of the visit include psychosocial referrals, environmental change, attention to adherence, and smoking cessation. Th ese children are followed up regularly and may still subsequently progress to further testing depending on how the asthma progresses. Supportive of this approach was a large, multifaceted randomized control intervention trial to address many of these points in inner-city children with asthma (35) . Th e intervention lasted a year, and the eff ect was still detectable at the end of a further year of follow-up.
Stages two and three: invasive investigations. If the child's problems persist, then a detailed program of tests is put in place (Table 5 ) (36) . In summary, the child has a detailed assessment of lung function, and airway infl ammation non-invasively, as well as a fi breoptic bronchoscopy, bron- 
Invasive studies
• Bronchoscopy, bronchoalveolar lavage, and bronchial biopsy • Intramuscular triamcinolone • pH study choalveolar lavage and endobronchial biopsy. A pH study is performed, and, during the anaesthetic, a single injection of depot triamcinolone 40-80 mg depending on the size of the child is administered. Th is ensures that the child has a real trial of steroids, and I will not diagnose steroid-resistant asthma unless such a trial has been performed. Th e symptoms, spirometry and non-invasive assessments of airway infl ammation are repeated 3-4 weeks later, and the child is assigned to a particular phenotype, and treatments proposed accordingly (discussed in more detail below and summarized in Table 6 ). Th is work has taught us very clearly that severe, therapy-resistant asthma is not one disease but many, and a single approach is not suffi cient.
Our previous manuscript (23) described the characteristics of problematic, severe asthma; they did not go through the nurse-led assessment prior to bronchoscopy. We have recently described the characteristics of children who had severe, therapy-resistant asthma (37) . Th ose with diffi cult asthma had been identifi ed at the fi rst step of the protocol; these children went on to Steps 2 and 3, aiming to defi ne their level of steroid responsiveness. One problem is that, unlike in adults, there is no generally accepted defi nition of steroid responsiveness in children. We have therefore broken this down into four components (Table 6 ). Th ere were 52 patients, of whom 30 were male; 44 (85%) were atopic, and 10 (19%) had previously been intubated. Th e median dose of inhaled fl uticasone was 1600 mcg, range 800 to 4000, and 20 (38%) were prescribed regular oral corticosteroids. Median ACT was 12/25, median FEV 1 was 70% (SD 21) and FeNO 48 ppb (range 4-169). All were on at least one controller (long-acting β-agonists), more than 50% were prescribed leukotriene receptor antagonists, and 20% were prescribed theophylline. Th e response to the steroid trial is shown in Table 7 . Eight of 52 (15%) were complete responders (all parameters), 36/52 (69%) partial responders (in at least one category) and 8/52 (15%) did not respond in any category (non-responders); 26/52 (50%) had evidence of ongoing infl ammation (either or both of raised FeNO or sputum eosinophilia) despite triamcinolone. Th us, steroid-resistant eosinophilic infl ammation is common in this group. Of course, further doses of triamcinolone may normalise this, and indeed steroid resistance is a spectrum, but this work does highlight the need for new approaches in a substantial number of children with severe, therapy-resistant asthma.
Severe, therapy-resistant asthma phenotypes Th e process described above is based on the supposition that airway infl ammation of various types, bronchial responsiveness and fi xed airfl ow obstruction may contribute independently to the clinical picture of severe, therapy-resistant asthma. I have no hesitation in rejecting the model that infl ammation causes bronchial responsiveness, which subsequently leads to PAL due to airway remodelling. Firstly, there is only the very poorest relationship between infl ammation and bronchial responsiveness (38) ; secondly, infl ammation may be reduced by treatment (monoclonal anti-IgE omalizumab, Xolair™) with no change in bronchial responsiveness (39) , and bronchial responsiveness may be reduced by treatment (the anti-TNFα strategy etanercept) with no change in infl ammatory parameters (40) ; and fi nally, structural airway wall changes may be independent of either, for example, as a result of intra-uterine or early life infl uences, including viral obliterative bronchiolitis (41) . Hence, we empirically phenotype the children on the basis of infl ammation, baseline airway calibre, and reactivity.
'Phenotyping' has become a trendy concept throughout medicine. A phenotype may be considered as a cluster of either clinical or pathological features which tend to be associated, and which are useful in some way, such as in managing the child or understanding the mechanisms of disease (42) . Th us, the concept of a phenotype is without value unless it leads to useful action. It must be stated that, as yet, the value of this approach has to be proven. Th ere is a real need for multi-centre studies, with very careful and uniform protocoldriven assessments, to confi rm or otherwise the value of these phenotypes. 
FeNO response
• Falls to normal (≤25 ppb)
Sputum response
• Eosinophil count falls to normal (<2.5%) Th e phenotypes we have described, and the approach we take to them, are summarised in Table 8 . Th ese are clearly still very broad categories, which require further detailed mechanistic exploration. Some of the limitations of the current approach (lack of measurement of distal infl ammation, single time point, use of single phenotyping of luminal and mucosal infl ammation) are discussed below.
A few explanatory comments are needed before treatment is considered. Some phenotypes are self-explanatory. We see some children who have apparently no airway infl ammation, but whose peak fl ows continue to fl uctuate wildly. It seems entirely illogical to treat such children with ever more powerful anti-infl ammatory medications, if apparently there is no infl ammation to treat. Th e use of subcutaneous terbutaline is discussed below. Another group is the child who becomes asymptomatic but who has persistent airway eosinophilia. It is worth recalling studies in adolescents and young adults who have 'outgrown' asthma -they were asymptomatic on no medications, but bronchial biopsy showed eosinophilic infl ammation identical to that seen in age-matched patients with ongoing symptomatic asthma (43) . Th e lesson is that the mere presence of a cell does not necessarily implicate it as the causative agent for severe symptoms.
Treatment of severe, therapy-resistant asthma in the older child Th ere is clearly no point in going through these detailed tests if no action results. Th e aim is to produce an individualised treatment plan for each child. It is important to distinguish two aspects of treatment, which are not the same (44):
• how can baseline asthma control be improved • (much more diffi cult) how can acute exacerbations be prevented. Much harm has arisen from confusing these two; it is arguable whether a child with good baseline control, judged on symptoms, lung function and non-invasive assessment of airway infl ammation, but with acute, viral-induced severe exacerbations, will benefi t from increases in baseline treatment.
Th e treatment themes that are important to consider are: • addressing the causes of secondary steroid resistance • the use of non-steroid based anti-infl ammatory therapy • the treatment of refractory airway hyper-reactivity • the avoidance of over-treatment of PAL • management of acute exacerbations.
Th ese will be considered in turn. Secondary steroid resistance. By defi nition, children with ongoing poor baseline asthma control are steroid-resistant. Th ere is still much work to be done on the molecular mechanisms and their treatment. Th is section focuses on causes of secondary steroid resistance that are preventable in the context in which I work, namely passive cigarette smoke exposure and indoor allergens; in other settings there may be other important factors such as air pollution and indoor biomass fuel exposure.
Cigarette smoke exposure. Th e fi rst step is to document that this is happening, with measurements of urine or sali- Th e mechanism may be by the induction of proinfl ammatory cytokine release by activation of NF-kappaB and posttranslational modifi cations of histone deacetylase in macrophages (this was a cell line study) (45) . Data in children are much sparser, but it seems likely that the eff ects of passive smoke exposure will be to induce steroid resistance. It is, of course, one thing to determine the cause, but another to persuade parents and older siblings to give up smoking. Indoor allergen exposure. Th is is a highly controversial area. House dust mite is one of the commonest allergens, and a recent Cochrane review (30) and a Lancet editorial (46) concluded that house dust mite avoidance was of no value whatever. Th e role of pet allergen avoidance was not discussed, but I believe that, contrary to these learned views, the case that allergens are a potential cause of steroid resistance and that allergen avoidance should be strenuously pursued in children with severe, therapy-resistant asthma, is overwhelming. Th e evidence on which allergen avoidance is denigrated is fl awed, and the interpretation of it is a classic example of the abuse of 'evidence-based' medicine -evidence is the servant to be interpreted by the experienced clinician in the light of the clinical situation, not the master which dictates every possible action. Th e fl aws include the following: inclusion of very short-term studies; inclusion of studies in which allergen avoidance was actually not achieved; including children and adults; and most critically, no adequately powered studies in children with severe, therapy-resistant asthma. Th is is critical, because to do allergen avoidance properly is expensive and time-consuming, and most unlikely to be achieved if the problems of the child are fairly trivial. Several strands of evidence argue in favor of allergen avoidance: • Biological plausibility: resistance to the actions of steroids on proliferating mononuclear cells can be achieved by coincubation with an allergen to which they are sensitized, via an interleukin (IL)-2 and -4 dependent mechanism (47, 48) . Th e detailed mechanisms are unclear, a change in isoforms of the glucocorticoid receptor has been implicated by some (49) but by no means all (50) workers. • Experimental studies: repeated low-dose inhalant allergen challenge, in a dose too low to lead to a change in FEV 1 leads to worsening of bronchial responsiveness and airway infl ammation (as judged by induced sputum) (51). • Observational studies: children who are cat-sensitive and are in a school class in which more than 18% of their class mates are cat owners develop a pattern akin to occupational asthma, progressively worsening during the week, improving at the weekend and in school holidays (52).
• Interactions with viral infections: in a study of children hospitalized for an acute attack of asthma, much the most signifi cant odds ratios for admission were for the combination of isolation of a respiratory virus, together with the combination of sensitization to an aeroallergen and high levels of exposure in the home to that allergen. Of these, reduction in allergen exposure is the only thing amenable to intervention (13) . Non-IgE-mediated eff ects of allergens also need to be considered. Many allergens are also proteases (53) and so could cause airway damage independent of any IgE eff ects. In a study of adult asthmatics, non-sensitized patients who were exposed to high levels of either HDM or dog allergen had worse airway infl ammation, as judged by FeNO, and worse bronchial responsiveness (54) . An epidemiological study in Europe showed a dose eff ect for cat allergen exposure, leading to worse bronchial responsiveness in atopic, non-cat sensitized people (55) . Very recent evidence has cast some light on the mechanisms of non-IgE-mediated house dust mite actions, interacting with the innate immune system via TLR-4 (56, 57) . Th is is particularly interesting, given the discovery of the importance of the epithelial expressed gene Filaggrin in the pathophysiology of atopic disease, further implicating the importance of epithelial permeability (58, 59) .
Th us, pending further intervention studies in severe, therapy-resistant asthma, it is and remains to advise stringent avoidance measures for all allergens to which the child is sensitised. Th us, any such furry pets must be removed, and conventional house dust mite measures, such as the use of mite-impermeable bedding covers, hot-washing the sheets, removal of bedroom carpets, and the avoidance of synthetic bedding) should be put in place. Even in the absence of IgEmediated sensitisation, there is a case for allergen avoidance.
Obesity. Th e relationships between obesity and asthma are complex. Asthma may lead to immobility and pre-dispose to obesity via this route and also because of the prescription of oral corticosteroids, and the obese child may complain of non-asthma breathlessness. However, obesity is a systemic pro-infl ammatory state, but paradoxically, obese asthmatics may have asthma with disproportionately low airway infl ammation (60) . Obesity is certainly a cause of steroid resistance (61) . Whether obesity or asthma came fi rst, in the individual child, it is important to tackle body weight issues in the obese. Th is is, of course, easy to say and harder to do.
Non-steroid-based anti-infl ammatory therapy. Th is would be indicated for ongoing infl ammation despite triamcinolone, or steroid-sensitive asthma which is requiring unacceptably high levels of steroids for adequate control. However, my experience is that a steroid-sparing strategy works much less well than steroids in those with steroid-sensitive asthma. Th e best non-steroid-based anti-infl ammatory documented therapy is the anti-IgE monoclonal antibody omalizumab (Xolair™). Th is expensive and inconvenient monoclonal antibody has been advocated as treatment for sever atopic asthma. In the UK, it is licensed for use in children over age 12 years (62) who have a total IgE of less than 700 iU/ml, but there is substantial clinical experience in the 6-12 age groups (63), so this is not an absolute contra-indication. If the child has a very high IgE, above present recommendations, which is not uncommon in severe, therapy-resistant asthma, then he / she may still benefi t from the top recommended dose (64) . To qualify for this expensive and inconvenient treatment, the child must have been admitted to hospital twice in a year, or have three exacerbations, one requiring admission, over the same time period, together with the need for high-dose medication chronically. Th is defi nition is open to criticism, because it would exclude a child on high-dose oral steroids, whose disease is controlled, but at the cost of potentially horrible side-eff ects. It would not seem reasonable to reduce treatment so that the child becomes ill in order to qualify for a trial of this medication. Our own criteria include having gone through the above detailed work-up, and have taken every reasonable precaution to exclude allergens from the environment. As yet, we do not have enough data to assess the likelihood of response, but we have seen so far more responders than non-responders.
Other agents are much less evidence-based. Macrolide antibiotics such as azithromycin have numerous anti-infl ammatory and anti-remodelling eff ects (65) (66) (67) and have been shown to be of proven benefi t in cystic fi brosis (68) (69) (70) (71) . Hypothetically, they may be useful in neutrophilic asthma (72) , but convincing evidence of long-term benefi t is lacking. Th ey also have activity in suppressing eosinophilic chemoattractants and thus might have a wider application (73) . Long-term, randomised controlled trials in both eosinophilic and neutrophilic asthma are awaited.
Th e evidence base for the treatment of neutrophilic asthma is minimal. My practice is fi rst to eliminate possible nonasthmatic causes of neutrophilic airway infl ammation, such as GER and aspiration, passive tobacco smoke exposure, and obstructive sleep apnoea (74) . If BAL culture is positive for bacteria, I would investigate for causes of chronic suppurative lung disease such as CF and PCD (above), and, if none is found, treat presumed persistent bacterial bronchitis (75, 76) with a prolonged course of antibiotics. If these approaches prove unrewarding and the child appears to have true neutrophilic asthma, then azithromycin for a 3-6 month trial is my fi rst strategy. Others to be considered include low-dose theophylline (anti-infl ammatory level), which accelerates neutrophil apoptosis (77), as well as potentially restoring steroid sensitivity by an eff ect on nuclear histone deacetylase activity (78) . A future option might be reduction of leukotriene B 4 activity with 5-lipoxygenase inhibition. Multi-centre trials for these proposed strategies are required.
Th e evidence for other steroid-sparing agents in paediatric severe, therapy-resistant asthma is minimal (79) . Choices include monthly intravenous immunoglobulin infusions (at least a six-month trial), oral low-dose methotrexate or azathioprine, and cyclosporin (80-82) (usually a three-month trial). Each has particular disadvantages, and the last three require regular and detailed monitoring from blood work, most intensively for cyclosporin. Possibly in the future, inhaled cyclosporin (83) or oral, more specifi c T-cell base strategies such as tacrolimus may be benefi cial. Th ere is no paediatric experience with cytokine-specifi c therapies such as anti-IL5 (21, 22) or etanercept (40) . Th e recent serious adverse events due to a cytokine storm with human monoclonals is a warning of the dangers of these approaches (84) . Aft er a detailed evaluation, and aft er an open discussion of the experimental nature of the above therapies, the potential for side-eff ects, and the lack of guarantees of success, the experienced paediatrician may embark on one or more therapeutic trials.
Th e treatment of refractory airway hyper-reactivity. Children who turn out to have marked peak fl ow lability, but no evidence of continued infl ammation, may respond to a continuous infusion of subcutaneous terbutaline, given by a portable Graseby or other pump, infused via a soft needle into the anterior abdominal wall (85) . It is unclear why this may work when inhaled long-acting β-2 agonists are not successful. Th is is a very demanding treatment, albeit occasionally dramatically successful. It is preceded by a detailed evaluation (above) and an in-patient, double blind trial (Table 9) to eliminate the large potential placebo eff ect of such treatment. Th e pharmacist prepares the syringes, and the child and family know that neither they nor the paediatricians or nurses will know which is the active treatment. Th e interpretation of the trial is complicated; the child may improve in hospital independent of the subcutaneous infusion because asthma therapy is directly observed! Th is is the likely explanation if the child improves in hospital independently of which treatment is infused. If, on the other hand, there is a consistent treatment eff ect with the active infusion, which is lost during the placebo infusion, then a genuine treatment eff ect is likely. During the trial, symptoms and bronchodilator use are scored daily, spirometry and acute bronchodilator reversibility are also performed daily, and the peak fl ow measured four hourly and the coeffi cient of variation recorded over each time period. Th e child, family, nurse and paediatrician all score out of ten their subjective impression of the success of each therapy. At the out-patient review, before the code is broken, the decision is taken as to whether a genuine treatment eff ect can be identifi ed. In the event that subcutaneous terbutaline is thought to be benefi cial, then the respiratory nurse trains the child and family in how to set it up. In selected patients, this demanding therapy may be well worthwhile. Th e avoidance of over-treatment of PAL. Th ere is clearly no point in escalating therapy to try to reverse irretrievably fi xed PAL. Th e usual cause is post-viral obliterative bronchiolitis, but GER and aspiration may also cause a similar picture. Th e usual picture is PAL despite triamcinolone and acute inhalation of β-2 agonists, with no elevation of FeNO or evidence of infl ammation on induced sputum. Medications should be weaned down with monitoring of acute bronchodilator reversibility and airway infl ammation; although asthma and obliterative bronchiolitis may co-exist, usually the element of reversibility in obliterative bronchiolitis is minimal, and therapy can largely be withdrawn.
Management of acute exacerbations. Th is is about the most diffi cult fi eld of all. Some attempts at prevention may be possible. Reduction of allergen exposure chronically in the home should be attempted (above), and avoidance of acute high-level exposure to allergen triggers is obviously sensible. Viral infections cannot be avoided, but infl uenza immunisation may be helpful and is certainly recommended. Titrating the regular anti-infl ammatory therapy to suppress even asymptomatic airway infl ammation may reduce exacerbations. Th e use of a single combination inhaler (Symbicort turbohaler™, the SMART strategy (86, 87) ) may also prevent exacerbations. However, many will be unpreventable. Acute deteriorations are managed according to standard guidelines (6) . An anecdotal strategy that may be useful for the really acute catastrophic deteriorations is the use of injectable adrenaline (Epipen™) while inhaled or nebulised β-2 agonist therapy is being prepared. Of course, all such patients should also have a course of oral steroids ready to hand. Much research is still needed into the prevention and management of exacerbations in the context of severe, therapy-resistant asthma.
Monitoring treatment of severe, therapy-resistant asthma Th ere are many studies looking at the role of 'infl ammometry' in the management of asthma, usually in the context of mild-moderate disease. 'Infl ammometry' may be used to titrate treatment, predict exacerbations, or indicate the likely success of treatment withdrawal. Th e characteristics of the ideal 'infl ammometer' are shown in Table 10 ; sadly, none such exists. Trials using FeNO (88) (89) (90) , sputum eosinophils (91, 92) and BHR (93, 94) have all shown benefi t, but it is fair to say that even in moderate asthma, the exact place of each method is unclear. A recent cluster analysis in adults (60) suggests it is those patients in which there is discordance between symptoms and infl ammation (either severe but asymptomatic infl ammation, or multiple symptoms without evidence of infl ammation) that are most likely to benefi t from 'infl ammometry' . Th e data on severe asthma are very sketchy. Preliminary work from our laboratory suggests that treating severe, therapy-resistant asthma by normalising sputum eosinophils, even if the child is asymptomatic, may reduce exacerbations (95) . Th is is another area for future research.
However, it is also very complex; in this severity-group, in our hands phenotypes may be inconstant (96) (below), and the relationship between FeNO and sputum eosinophils may vary between individuals, and within the same individual over time, illustrating the complexity of the problem (97) .
Phenotyping asthma in the older child: what is the future? Th e phenotyping process described above depends on a single time point, with measurements of proximal events. Furthermore, the diff erences between mucosal and luminal phenotypes have not been addressed.
Is mucosal or luminal infl ammation important? We have shown that there is only the poorest correlation between bronchial mucosal eosinophilia and eosinophil counts in either sputum or BAL. It is unclear which determines clinical phenotype. Th e literature is confl icting on the importance of mucosal eosinophilia. In one study (43) , endobronchial biopsy was compared in three groups of young adults -active asthmatics, asthma in remission, and normals. Th e asthmatics in remission had no symptoms and were taking no treatment, but they had the same extent of airway wall eosinophilia as the active asthmatics. Clearly, mucosal eosinophilia on its own is insuffi cient to cause asthma. Th e distribution of infl ammatory cells, rather than actual numbers, may be important; the clinical phenotypes of asthmatics and adult patients with eosinophilic bronchitis are determined by the distribution of mast cells, with smooth muscle mast cells being the determinant of classical asthma (98, 99) .
By contrast, data from anti-IL5 studies suggest that mucosal eosinophilia may be important. Intravenous infusions of anti-IL5 lead to complete abrogation of sputum and blood eosinophilia, but had no eff ect on bronchial responsiveness in a group of mild adult asthmatics (100). However, when in another study endobronchial biopsies were examined, it was found that anti-IL5 had only halved the mucosal eosinophil count and had had no eff ect on major basic protein staining. It was suggested that the poor response was due to the failure to improve the mucosal pathology (101) .
In summary, it is as yet unknown whether mucosal or luminal eosinophils are most important in driving the clinical asthma phenotype, and how to manage any discordance between the two. A real handicap is the lack of biomarkers relating to airway wall disease, comparable to the use of sputum for luminal changes.
Th e time domain: are phenotypes stable? Underpinning the strategy of normalising sputum eosinophil counts and ignoring symptoms, which has been successfully employed in adults, is the assumption that cellular phenotypes remain stable over time. Th is is not the case in severe, therapy-resistant asthma in children. In one study, more than 40% children showed at least one switch in sputum cellular phenotype over a one year period (96) . It is certainly not right to assume that assigned phenotypes will remain stable over time. What is unclear is how frequently children should be re-phenotyped and what these changes actually mean, i. e. whether they represent a real change in the fundamental nature of the disease, or refl ect transient environmental infl uences such as viral infection, allergen load or pollution.
Proximal versus distal infl ammation: what matters? Adult studies have utilised transbronchial biopsy (TBB) to determine alveolar infl ammation in asthmatics (102) (103) (104) . Distal infl ammation with CD4-positive lymphocytes correlated with nocturnal asthma. TBB has a signifi cant risk of bleeding and pneumothorax in children (105) , and it is diffi cult to see how it could be used as a research technique. It would need to be shown that diagnosing distal infl ammation gives extra benefi t to the individual child in planning treatment, which has yet to be done.
If TBB cannot be used, what other techniques might help? In the context of CF, fractionating BAL showed that the fi rst aliquot had diff erent cellularity from pooled subsequent aliquots, and it was suggested that the latter represented an alveolar sample as against the fi rst aliquot which represented the larger bronchi (106) . Th is approach could be followed in asthma, but as yet it has not been studied. An approach used in adults has been the use of fi ne sampling probes which can be advanced into the very distal airways.
Another alternative is to partition NO production into airway (J NO ) and alveolar (C ALV ), by measuring NO production at diff erent expiratory fl ow rates (107) . We have shown that in children J NO and FeNO 50 correlate closely. As has been described before, both J NO and FeNO 50 are elevated in atopic asthmatics but also in atopic non-asthmatics. However, C ALV was only elevated in atopic asthmatics. Both J NO and C ALV were elevated in poorly controlled asthmatics. In one adult study, C ALV was used to monitor the response to treatment with ciclesonide, on the assumption that it would be more eff ective in treating infl ammation distally (108) . Th e group did show a fall in C ALV with ciclesonide treatment, but the overlap between groups was so great that C ALV did not seem likely to be useful in monitoring individuals.
Another approach might be to study distal airway function, albeit acknowledging that the function, at least in the proximal airways, does not necessarily correlate well with infl ammation. Th e distal-most airways have historically been a 'silent area' , because more than 90% can be obstructed before a signal shows up with spirometry. Recent developments include the analysis of lung wash-in and wash-out inert gas curves, calculating lung clearance index, and sophisticated partitioning of abnormalities to the conducting airways (S COND ) and the acini (S ACIN ) (109) (110) (111) . More data are needed before we can determine whether these measurements will enable us to detect peripheral infl ammation.
CT indices of air trapping might be another approach, but the problems would include standardising the scans, in particular the lung volumes at which they are taken; the structural changes may represent remodelling, not infl ammation; and the radiation dose.
Distal airways disease may be dissociated from proximal airway changes by the eff ects of treatment. Medication deposition in the most distal airways is problematic, but with the advent of fi ne-particle aerosols, such as HFA-beclomethasone (112) and ciclesonide (11) , this problem may be addressed. An alternative might be low-dose oral steroids (say, 0.05 mg/kg) to ensure distal steroid delivery. What is now needed is to know whether (a) distal infl ammation is truly signifi cant in severe, therapy-resistant asthma, and (b) how we can monitor the eff ects of treatment.
Mathematical analysis. Conventionally, phenotypes are described by data inspection, but increasingly mathematical techniques such as principal component analysis are used to tease out objective phenotypes. Th ese analyses require a large data set and preferably need to be validated on another cohort. A word of caution is necessary; although more objective than data inspection, these techniques are also vulnerable. Critical is the nature and quality of the information inputted, which in turn relies on the presuppositions and assumptions of the investigator. If crucial data are omitted, the analyses will fail to reveal important associations.
SUMMARY
We have a long way to go before we understand the phenotyping of severe asthma. At this stage, we do not even know whether true non-eosinophilic asthma exists; it may be that we are not looking for eosinophils in the right compartment. Indeed, a very small sputum study, which showed that the response to steroids was independent of sputum cellularity, might suggest this was the case. Th ere is a real need for non-invasive biomarkers of distal airway and also mucosal disease.
